UCB

News

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre

News

FDA approves UCB’s Cimzia in plaque psoriasis

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis

News

Science 37 UCB pharma virtual clinical trials

UCB collaborates with Science 37 on virtual clinical trials

UCB is changing the way it conducts some of its research studies, removing the need for patients to attend hospitals by allowing them to take part in virtual clinical trials at home.

Views & Analysis

Can ‘design thinking’ revolutionise pharma’s culture?

As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how the company is creating a culture based around ‘design thinking’.

News